Compare VERI & NYXH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VERI | NYXH |
|---|---|---|
| Founded | 2014 | 2009 |
| Country | United States | Belgium |
| Employees | N/A | N/A |
| Industry | EDP Services | Medical/Dental Instruments |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 142.2M | 161.9M |
| IPO Year | 2017 | 2021 |
| Metric | VERI | NYXH |
|---|---|---|
| Price | $1.31 | $1.75 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 3 |
| Target Price | $7.00 | ★ $9.33 |
| AVG Volume (30 Days) | ★ 2.8M | 521.0K |
| Earning Date | 04-15-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $92,637,000.00 | N/A |
| Revenue This Year | $52.20 | $213.98 |
| Revenue Next Year | $3.06 | $126.25 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.27 | $1.26 |
| 52 Week High | $9.42 | $8.59 |
| Indicator | VERI | NYXH |
|---|---|---|
| Relative Strength Index (RSI) | 34.56 | 40.64 |
| Support Level | N/A | $1.26 |
| Resistance Level | $2.35 | $3.36 |
| Average True Range (ATR) | 0.12 | 0.12 |
| MACD | 0.01 | 0.07 |
| Stochastic Oscillator | 9.21 | 88.64 |
Veritone Inc is a provider of artificial intelligence (AI) computing solutions and services. It generates revenue through the delivery of its Software Products and Services which consists of revenues generated from Commercial Enterprise and Government and Regulated Industries customers using the company's aiWARE platform and hiring solutions, any related support and maintenance services, and any related professional services associated with the deployment and/or implementation of such solutions, Managed Services which consist of revenues generated from Commercial Enterprise customers using company's content licensing services, advertising agency, influencer management and related services. It has presence in the United States, the United Kingdom, France, Australia, Israel, and India.
Nyxoah SA is a health-technology company focused on the development and commercialization of solutions and services to treat sleep-disordered breathing conditions. The company's solution platform is based on the Genio system, a CE-Mark validated, user-centered, bilateral neurostimulation therapy to treat moderate to severe Obstructive Sleep Apnea (OSA), the common sleep disordered breathing condition that is associated with increased mortality risk and comorbidities including cardiovascular diseases, depression and stroke.